# PLCXD3

## Overview
PLCXD3 is a gene that encodes the protein phosphatidylinositol-specific phospholipase C X domain containing 3, which is a member of a novel class of phospholipase C enzymes. This protein is characterized by the presence of the catalytic X domain, distinguishing it from other phospholipase C enzymes that typically contain additional regulatory domains. The PLCXD3 protein plays a crucial role in cellular signaling, particularly in pancreatic β-cell function, where it is involved in insulin signaling and glucose sensing. It is highly expressed in human islets and is essential for the hydrolysis of membrane phospholipids in response to external stimuli, a process vital for insulin secretion. The gene is located on chromosome 5 at position 5p13.1 in humans and has been implicated in various metabolic and neurological disorders due to its role in regulating key cellular processes (Gellatly2012Cloning; Aljaibeji2019Reduced).

## Structure
PLCXD3 encodes a protein that is part of a novel class of phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, characterized by the presence of only the catalytic X domain. The full-length cDNA of PLCXD3 is 965 base pairs long, encoding a protein of 321 amino acid residues (Gellatly2012Cloning). This protein is smaller than other mammalian phospholipase Cs, which typically contain additional regulatory domains such as the Y-box, pleckstrin homology (PH) domain, and C2 domain (Gellatly2012Cloning).

The primary structure of PLCXD3 includes conserved catalytic histidines, which are essential for its enzymatic activity, similar to the PI-PLC enzyme from Bacillus cereus, despite sharing only 33% amino acid identity with it (Gellatly2012Cloning). The conservation of these histidines suggests that PLCXD3 retains similar catalytic properties to its bacterial counterpart. The gene is located on chromosome 5 at position 5p13.1 in humans (Gellatly2012Cloning).

While specific details on the secondary, tertiary, and quaternary structures of PLCXD3 are not provided, the presence of the X domain indicates a potential for specific folding patterns that facilitate its enzymatic function. The study does not mention post-translational modifications or splice variant isoforms for PLCXD3.

## Function
The PLCXD3 gene encodes a protein that plays a significant role in pancreatic β-cell function, particularly in insulin signaling and glucose sensing. It is one of the most highly expressed phosphoinositide-specific phospholipase C (PI-PLC) subtypes in human islets, where it is involved in the hydrolysis of membrane phospholipids in response to external stimuli. This process is crucial for insulin secretion and β-cell function (Aljaibeji2019Reduced).

In healthy human cells, PLCXD3 expression correlates positively with insulin and GLP1R expression, and inversely with body mass index (BMI) and glycated hemoglobin (HbA1c) levels. This suggests its involvement in maintaining normal insulin function and glucose metabolism (Aljaibeji2019Reduced). Silencing PLCXD3 in INS-1 cells leads to reduced glucose-stimulated insulin secretion and downregulation of key insulin signaling and biosynthesis genes, indicating its critical role in these pathways (Aljaibeji2019Reduced).

PLCXD3 is also involved in regulating PtdIns(4,5)P2 levels on endosomes, a function that is conserved across species. This regulation is essential for cell growth, division, and migration, highlighting the gene's broader role in cellular signaling and communication (Mondin2019PTEN).

## Clinical Significance
Mutations and altered expression of the PLCXD3 gene have been implicated in several metabolic and neurological disorders. In the Emirati population, specific genetic variants of PLCXD3, namely rs319013 and rs9292806, are associated with an increased risk of metabolic syndrome (MetS). These variants are linked to higher fasting glucose levels, increased HbA1c, and lower HDL-cholesterol levels, although they do not appear to increase the risk of type 2 diabetes (T2D) (Aljaibeji2020Genetic). The GC haplotype of these SNPs is more prevalent in individuals with MetS, suggesting a genetic predisposition to this condition (Aljaibeji2020Genetic).

Reduced expression of PLCXD3 in pancreatic β-cells is associated with impaired insulin secretion and disruptions in glucose sensing and insulin signaling. This downregulation affects the expression of key genes involved in insulin biosynthesis and signaling pathways, potentially contributing to the pathophysiology of diabetes (Aljaibeji2019Reduced).

In the context of neurological disorders, PLCXD3 has been investigated for its potential role in prion diseases, such as Creutzfeldt-Jakob disease (CJD). While some studies have suggested an association between PLCXD3 variants and CJD, others have found no significant link, indicating that the clinical significance of PLCXD3 mutations in these diseases may be limited (Balendra2016Variants; Bishop2013Splice).


## References


[1. (Balendra2016Variants) Rubika Balendra, James Uphill, Claire Collinson, Ronald Druyeh, Gary Adamson, Holger Hummerich, Inga Zerr, Pierluigi Gambetti, John Collinge, and Simon Mead. Variants of plcxd3 are not associated with variant or sporadic creutzfeldt-jakob disease in a large international study. BMC Medical Genetics, April 2016. URL: http://dx.doi.org/10.1186/s12881-016-0278-2, doi:10.1186/s12881-016-0278-2. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12881-016-0278-2)

[2. (Mondin2019PTEN) Virginie E. Mondin, Khaled Ben El Kadhi, Clothilde Cauvin, Anthony Jackson-Crawford, Emilie Bélanger, Barbara Decelle, Rémi Salomon, Martin Lowe, Arnaud Echard, and Sébastien Carréno. Pten reduces endosomal ptdins(4,5)p2 in a phosphatase-independent manner via a plc pathway. Journal of Cell Biology, 218(7):2198–2214, May 2019. URL: http://dx.doi.org/10.1083/jcb.201805155, doi:10.1083/jcb.201805155. This article has 13 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1083/jcb.201805155)

[3. (Gellatly2012Cloning) Steven A. Gellatly, Svetlana Kalujnaia, and Gordon Cramb. Cloning, tissue distribution and sub-cellular localisation of phospholipase c x-domain containing protein (plcxd) isoforms. Biochemical and Biophysical Research Communications, 424(4):651–656, August 2012. URL: http://dx.doi.org/10.1016/j.bbrc.2012.06.079, doi:10.1016/j.bbrc.2012.06.079. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2012.06.079)

[4. (Aljaibeji2020Genetic) Hayat Aljaibeji, Abdul Khader Mohammed, Sami Alkayyali, Mahmood Yaseen Hachim, Hind Hasswan, Waseem El-Huneidi, Jalal Taneera, and Nabil Sulaiman. Genetic variants of the plcxd3 gene are associated with risk of metabolic syndrome in the emirati population. Genes, 11(6):665, June 2020. URL: http://dx.doi.org/10.3390/genes11060665, doi:10.3390/genes11060665. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes11060665)

[5. (Bishop2013Splice) Matthew T Bishop, Pascual Sanchez-Juan, and Richard SG Knight. Splice site snps of phospholipase plcxd3 are significantly associated with variant and sporadic creutzfeldt-jakob disease. BMC Medical Genetics, September 2013. URL: http://dx.doi.org/10.1186/1471-2350-14-91, doi:10.1186/1471-2350-14-91. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-14-91)

[6. (Aljaibeji2019Reduced) Hayat Aljaibeji, Debasmita Mukhopadhyay, Abdul Khader Mohammed, Sarah Dhaiban, Mahmood Y. Hachim, Noha M. Elemam, Nabil Sulaiman, Albert Salehi, and Jalal Taneera. Reduced expression of plcxd3 associates with disruption of glucose sensing and insulin signaling in pancreatic β-cells. Frontiers in Endocrinology, November 2019. URL: http://dx.doi.org/10.3389/fendo.2019.00735, doi:10.3389/fendo.2019.00735. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2019.00735)